Milestone! Wanze's Innovative Four-Strain Live-Bacteria Drug KAL-001 Achieves Major Breakthrough with First Patient Enrolled in Phase III Trial

Health Care

A Chinese pharmaceutical company's innovative live-bacteria drug for recurrent vaginal infections clears a key clinical milestone, marking a potential shift in how bacterial vaginosis is treated.

BEIJING — For millions of women, a diagnosis of bacterial vaginosis is only the beginning. Within three months of treatment, up to 40% will see the infection return, trapped in a cycle that current therapies have done little to break.

On June 29, 2026, a small but determined player in China's biotech sector said it had taken a meaningful step toward ending that cycle. Guangzhou Wanze Medicine Chain Co., Ltd. — the Greater China commercialization partner for an innovative four-strain live-bacteria drug called KAL-001 — announced that the first patient had been enrolled in its Phase III clinical trial for the bacterial vaginosis indication.

The enrollment of that first subject, at one of 19 research centers nationwide, formally moves the trial from planning into full execution: recruiting patients, administering the drug, and, eventually, measuring whether KAL-001 can deliver on its promise of lasting relief.

"The registration clinical trial of innovative live-bacteria biologics is of milestone significance for advancing the upgrade of treatment paradigms in this field," said Zhu Lan, an academician at the Chinese Academy of Medical Sciences who chaired the investigator meeting for the trial in February.

A Recurrence Problem

Bacterial vaginosis, or BV, is the most common vaginal infection among women of reproductive age. According to China's 2021 revised clinical guidelines for BV diagnosis and treatment, the one-month recurrence rate after standard therapy reaches 20%. By three months, it climbs to 40%.

The root cause, researchers say, lies in the limits of conventional treatment. Existing therapies suppress the pathogens that cause symptoms but fail to restore the vaginal microbiome to its natural, healthy state. The result is a condition that keeps coming back.

KAL-001 is designed to address that gap. The drug combines four carefully selected strains of Lactobacillus, formulated to closely mimic the natural microbial ecosystem of a healthy vagina. The strains work through multiple mechanisms — producing lactic acid to maintain an acidic environment, releasing hydrogen peroxide to inhibit pathogens, competing for attachment sites on vaginal epithelial cells, and competing for nutrients — all aimed at restoring balance at the source rather than simply suppressing symptoms.

A First-of-Its-Kind in China

KAL-001 is the first vaginally administered multi-strain live-bacteria drug to enter clinical trials in China. The Phase III study uses a multi-center, randomized, double-blind, placebo-controlled design — widely regarded as the gold standard in clinical research — with the core objective of systematically validating both the efficacy and safety of KAL-001 in reducing BV recurrence rates.

Wanze Medicine, a subsidiary of listed company Wanze Shares (stock code: 000534), has been deeply involved in the trial's operations, drawing on more than three decades of experience in the microecological pharmaceutical space. The company is the exclusive Greater China partner for both the industrialization and commercialization of KAL-001, which was developed by Sichuan Anaerobic Biology — a company that operates one of China's leading human microbiome strain resource banks.

The partnership reflects a deliberate division of labor: Sichuan Anaerobic Biology brings the upstream science — strain screening, isolation, preservation, production, and evaluation — while Wanze Medicine provides the downstream capabilities to carry the drug through clinical development, regulatory approval, and, ultimately, market launch.

A Broader Pipeline

KAL-001 is not the only candidate moving through the pipeline. The two companies are also collaborating on KAL-002, a Class 1 innovative drug for gastrointestinal diseases. Described as China's first approved intestinal-formula bacterial drug to enter clinical trials, KAL-002 has advanced to Phase II, with early data showing favorable safety, tolerability, and efficacy signals.

For Wanze Medicine, the stakes extend beyond any single drug. The company is best known for two established microecological brands — Jinshuangqi, a national Class 1 new drug, and Dingjunsheng, an exclusive gynecological microecological preparation. It has built what it calls a full-chain closed loop spanning research and development, technology transfer, manufacturing, and commercialization, with a sales network reaching major medical institutions across China.

The Phase III enrollment milestone for KAL-001, the company said, represents a critical node in its strategy to pair mature, revenue-generating products with an innovative pipeline — a dual-engine model aimed at sustaining long-term growth in China's rapidly expanding biotech sector.

Whether KAL-001 can ultimately deliver on its scientific promise will depend on the trial data still to come. But for a condition that has long defied durable solutions, the arrival of a four-strain live-bacteria drug in late-stage testing offers something that has been in short supply: a reason to be cautiously optimistic.

Source: China Pharmacy / Original reporting. All financial data denominated in Chinese yuan (RMB) unless otherwise noted.